Cashu
FDA Approves Palynziq for PKU: A Milestone in Rare Disease Treatment Innovation
6 days ago
Stocks
Health Care
fold
Amicus Therapeutics
NASDAQ: FOLD
-0.00 (-0.03%)
14.365
USD
At close at Mar 10, 20:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
4.43B
Dividend Yield
0.00%
P/E Ratio
-163.54
EPS
-0.18
Revenue
528.29M
Avg. Volume
4.04M
About
What does FOLD do?
Amicus Therapeutics, a Philadelphia-based biotechnology company with 517 employees, went public in 2007 and markets Galafold for Fabry disease and Pombiliti + Opfolda for late-onset Pompe disease. Galafold stabilizes alpha-Gal A enzyme, while Pombiliti + Opfolda enhances enzyme uptake in relevant tissues.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.